Hatch BioFund Announces Investment in Optimeos Life Sciences to Advance Novel Nanoparticle Platform for the Delivery of Therapeutic Nucleic Acids and Proteins
Early-stage life sciences fund backs Princeton University spinout pioneering a novel, best-in-class nanoparticle platform for targeted gene therapy
Hatch BioFund, an early-stage life sciences venture capital firm headquartered at the Pennsylvania Biotechnology Center in Doylestown, PA ("Hatch"), today announced an investment in Optimeos Life Sciences, Inc., a Princeton University spinout developing a proprietary nanoparticle platform for the intracellular delivery of therapeutic macromolecules, including RNA, DNA and proteins (“Optimeos”).
Optimeos, with headquarters in Princeton, NJ, has developed a highly differentiated, non-viral nanoparticle drug delivery platform based on a patented process called Coated Inverse Nanocarriers (CINCs), refined over two decades in the laboratory of Princeton University Professor Robert Prud'homme. The technology enables the robust, scalable encapsulation of multiple payload types, including biologics, peptides, RNA, and DNA, into customizable nanocarrier particles with encapsulation efficiencies exceeding 90 percent. Optimeos’ platform enables modular tissue targeting, tunable immunogenicity, and a superior dosing profile, as demonstrated in the company’s lead program, a gene replacement therapy for the rare disease CTLN1, and in its additional pipeline programs, which are directed at T cell engineering and targeted pulmonary applications. Optimeos is actively partnering with biopharmaceutical companies to develop next-generation therapeutics across a broad range of diseases.
